SNPMiner Trials (Home Page)
Report for Mutation T351I
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
NCT03615105 Acute Lymphoid Leukemia (ALL) Acute Myeloid Leukemia (AML) Chronic Myeloid Leukemia (CML) Hodgkin Lymphoma Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia Radiation: Hyperfractionated total body irradiation Drug: Thiotepa Drug: Cyclophosphamide Drug: Busulfan Drug: Fludarabine Drug: Melphalan Drug: Clofarabine Procedure: HPC(A) stem cell allograft Drug: Rituximab Device: Rabbit antithymocyte globulin MeSH:Lymphoma Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma
HPO:Acute megakaryocytic leukemia Acute myeloid leukemia Chronic lymphatic leukemia Chronic myelogenous leukemia Leukemia Lymphoid leukemia Lymphoma Myeloid leukemia
T351I mutation). --- T351I ---
Primary Outcomes
Description: The intervention will be considered unpromising if the rate of GVHD is greater than 40% and promising if the rate is 20% or less.
Measure: the number of incidences of grade 3-4 acute GVHD Time: 2 years